Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis

Wang, Haoyu; Yang, Ruiyuan; Cheng, Cheng; Wang, Suyan; Liu, Dan; Li, Weimin

doi:10.1080/01635581.2023.2294522

Nutrition and Cancer

2023

DOI: 10.1080/01635581.2023.2294522

|View full text |Cite

Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis

Haoyu Wang,

Ruiyuan Yang,

Cheng Cheng

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Analysis and Validation of the Glasgow Prognostic Score (GPS) for Predicting 14-, 21-, and 30-Day Mortality in End-Stage Cancer Patients

Huang,

Yang

2024

Preprint

View full text Add to dashboard Cite

Background: The Glasgow Prognostic Score (GPS) is commonly used to evaluate cancer patient prognosis. Early initiation of palliative care for end-stage cancer patients is crucial in providing comfort and preparing both patients and their families for a peaceful death. This study aimed to assess the value of GPS in predicting short-term mortality in end-stage cancer patients. Methods: A retrospective analysis of in-hospital cancer deaths at a medical center in Taiwan over a five-year period was conducted. The discriminative ability, accuracy, sensitivity, specificity, and positive and negative predictive values of GPS were evaluated using the area under the receiver operating characteristic curve (AUC) for predicting 30-, 21-, and 14-day mortality. Results: Among the 5,315 in-hospital cancer deaths between 2009 and 2013, 78% of patients died within 30 days of admission (mean hospital stay = 12 days). The GPS scoring model’s predictive ability for short-term mortality was suboptimal for this cancer population (AUC = 0.548, 95% CI: 0.526–0.571). Although sensitivity was high (79.2%), specificity was low (30.3%), and overall accuracy was 68.0%. Conclusion: The GPS scoring model has high sensitivity and may serve as a reference for initiating palliative care in end-stage cancer patients. However, due to its low specificity, caution should be exercised in applying GPS scores for end-of-life care planning and patient communication, as it does not accurately predict patient death.

show abstract

Analysis and Validation of the Glasgow Prognostic Score (GPS) for Predicting 14-, 21-, and 30-Day Mortality in End-Stage Cancer Patients

Huang,

Yang

2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis

Cited by 1 publication

References 37 publications

Analysis and Validation of the Glasgow Prognostic Score (GPS) for Predicting 14-, 21-, and 30-Day Mortality in End-Stage Cancer Patients

Analysis and Validation of the Glasgow Prognostic Score (GPS) for Predicting 14-, 21-, and 30-Day Mortality in End-Stage Cancer Patients

Contact Info

Product

Resources

About